BioAge Labs (NASDAQ:BIOA) Downgraded by Wall Street Zen to Sell

Posted by Francis Steltz on May 18th, 2026

Wall Street Zen downgraded shares of BioAge Labs (NASDAQ:BIOA – Free Report) from a hold rating to a sell rating in a report published on Sunday.

A number of other equities research analysts also recently issued reports on the stock. Piper Sandler began coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating on the stock. Morgan Stanley set a $23.00 target price on BioAge Labs in a report on Wednesday, February 4th. Needham & Company LLC started coverage on BioAge Labs in a report on Friday, March 27th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Finally, Citigroup boosted their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioAge Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

View Our Latest Research Report on BIOA

BioAge Labs Stock Performance

BIOA stock opened at $17.66 on Friday. The company’s 50-day simple moving average is $18.15 and its 200 day simple moving average is $15.88. BioAge Labs has a 52 week low of $3.79 and a 52 week high of $24.00. The company has a market capitalization of $784.99 million, a PE ratio of -7.36 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million for the quarter. On average, analysts forecast that BioAge Labs will post -2.59 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Octagon Capital Advisors LP grew its holdings in shares of BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of BioAge Labs during the 4th quarter valued at approximately $13,892,000. Geode Capital Management LLC grew its holdings in shares of BioAge Labs by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after purchasing an additional 28,646 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of BioAge Labs by 113.4% during the 4th quarter. State Street Corp now owns 422,846 shares of the company’s stock valued at $5,594,000 after purchasing an additional 224,735 shares during the last quarter.

BioAge Labs Company Profile

(Get Free Report)

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.